4.5 Review

The Relationship Between Neurocognitive and Psychosocial Functioning in Major Depressive Disorder: A Systematic Review

期刊

JOURNAL OF CLINICAL PSYCHIATRY
卷 75, 期 12, 页码 1359-1370

出版社

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.13r08939

关键词

-

资金

  1. Alcohol Beverage Medical Research Council
  2. AstraZeneca Canada
  3. Canadian Institutes of Health Research
  4. CNS Vital Signs
  5. ImPACT Applications
  6. Lundbeck Canada
  7. Pfizer Canada
  8. Psychological Assessment Resources (PAR)
  9. Rehabilitation Research and Development (RR&D) Service of the US Department of Veterans Affairs
  10. AstraZeneca
  11. Bristol-Myers Squibb
  12. Eli Lilly
  13. GlaxoSmithKline
  14. Johnson Johnson
  15. Novartis
  16. Pfizer
  17. Abbott
  18. Servier
  19. Wyeth
  20. Stanley Foundation
  21. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  22. Canadian Psychiatric Foundation
  23. Canadian Psychiatric Association Foundation
  24. Litebook
  25. Lundbeck
  26. Merck
  27. St Jude Medical
  28. UBC Institute of Mental Health/Coast Capital Savings

向作者/读者索取更多资源

Objective: Neurocognitive deficits are demonstrated in major depressive disorder (MDD) and most likely contribute to the functional impairment experienced by affected individuals. We systematically reviewed the evidence on neurocognitive deficits and their relationship(s) to psychosocial functioning in MDD. Data Sources: English-language literature was searched in MEDLINE, EMBASE, Science Direct, and PsycInfo databases for the years 1980-October 15, 2013, with the following terms: (depressive disorder or depressive disorder, major) and permutations of (cognitive, neurocognitive, neuropsych*) with (impairment, deficit, performance, test) and (quality of life; functional outcomes; outcome assessment, health care) or (assessment, outcomes; assessment, patient outcomes; outcomes assessment; outcomes assessments, patient). Study Selection: Inclusion criteria were (1) nongeriatric adults (<60 years) with a primary diagnosis of MDD by DSM-IV, ICD-9, or ICD-10 criteria; (2) use of neuropsychological tests; and (3) use of a specific measure of social, occupational, or daily functioning. Of 488 articles identified in the initial search, 10 met the inclusion criteria. Data Extraction: Two independent appraisers assessed eligibility of the studies. Substantial heterogeneity in the samples and methods precluded a quantitative meta-analysis, so we performed a narrative descriptive review. Results: The included studies employed a variety of neurocognitive tests and assessments of psychosocial functioning. Overall, depressed samples had neurocognitive deficits in various domains that were associated with different measures of psychosocial functioning. However, these findings were constrained by methodological limitations of studies. Conclusions: The limited evidence base suggests that neurocognitive functioning appears to be broadly associated with functional impairment in individuals with MDD, but the quality of evidence is weak. Further studies to clarify the relationship(s) between neurocognitive and psychosocial functioning in MDD will benefit from larger and more homogeneous samples, prospective designs with multivariate analyses, and use of comprehensive assessments of psychosocial functioning that are validated in depressed populations. (C) Copyright 2014 Physicians Postgraduate Press, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据